NCT05602207

Effects of Abrocitinib in Subjects With Atopic Dermatitis With an Unsatisfactory Response After Treatment With Dupilumab

Clinical and Molecular Effects of Abrocitinib in Subjects With Atopic Dermatitis With an Unsatisfactory Response or Facial Erythema After Treatment With Dupilumab

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Innovaderm Research Inc. · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a single-arm, open-label study that will examine the effect of abrocitinib in subjects with atopic dermatitis.

Detailed description

This study is being conducted to evaluate the efficacy, safety, and molecular effects of abrocitinib in subjects with an unsatisfactory response or facial erythema after at least 12 weeks of treatment with dupilumab. Approximately 60 subjects with atopic dermatitis will receive abrocitinib once daily for 12 weeks.

Conditions

• Atopic Dermatitis

Interventions

Type	Name	Description
DRUG	Abrocitinib	100 mg Abrocitinib once daily (QD) for 12 weeks

Timeline

• Start date: 2022-11-25
• Primary completion: 2024-12-03
• Completion: 2025-01-09
• First posted: 2022-11-02
• Last updated: 2025-03-28

Locations

12 sites across 2 countries: United States, Canada

Regulatory

• FDA-regulated drug study